REG - Allergy Therapeutics - Annual Report and Accounts Delayed

Allergy TherapeuticsAnnouncement

29/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221229:nRSc1217La&default-theme=true

RNS Number : 1217L  Allergy Therapeutics PLC  29 December 2022

 

 

Allergy Therapeutics plc
("Allergy Therapeutics" or the "Company")

 

Publication of Annual Report and Accounts Delayed

Suspension of Shares

 

29 December 2022 Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, announces
that due to delays in completing the audit for the year ended 30 June 2022,
it will not publish its annual report and accounts by 31 December 2022.
Consequently, the shares of the Company will be suspended from trading from
7.30am on 3 January 2023.

 

The Company announced its unaudited preliminary results on
29 September 2022, and it is not aware of any material change that will be
required to be made to the results, and it is actively working to finalise the
audit and publication of its annual report and accounts.

 

As previously announced, the Company is actively reviewing all funding options
following the voluntary pause in production that has led to the need for
significant additional near-term funding. The Company is in active discussions
on funding and will update the market in due course.

 

For further information on the Company, please visit the website:
www.allergytherapeutics.com (http://www.allergytherapeutics.com) .

 

This announcement contains inside information for the purposes of Article 7 of
Regulatory (EU) No596/2014.

 

-  ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0)1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0)20 7886 2500

Freddy Crossley, Emma Earl, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 (0)20 3709 5700

Mary-Jane Elliott / David Daley / Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

Notes for editors:

 

About Allergy Therapeutics

 

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group, which
employs c.600 employees, is listed on the London Stock Exchange (AIM:AGY). For
more information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSFLFIDFALTFIF